Purpose:
The objective of this request for applications (RFA) is to support research that will advance the development of vaccines, adjuvants, therapeutics, immunotherapeutics, and diagnostics that are specific for National Institute of Allergy and Infectious Diseases (NIAID) Category A, B, or C priority pathogens or toxins. Research is not required to result in a “final” product but must advance the development of a candidate product.
A second objective of this RFA is to stimulate scientifically sound, original, and innovative research requiring a comprehensive team and multidisciplinary effort that is likely to advance promising candidate products or platform technologies through the product development pathway. Applications proposing the development of a previously identified candidate vaccine, therapeutic, adjuvant, or diagnostic product that has demonstrated proof of concept against any of the NIAID Category A, B, or C priority pathogens or toxins are strongly encouraged.
Although clinical development strategies may be included within an overall product development plan, this RFA will not support phase I, II, and III clinical trials or field trials. Applications requesting support for clinical trials will be viewed as unresponsive to this RFA and will be returned to the applicant without review. However, use of appropriate human cell lines and human-derived material in preclinical studies in support of complying with regulatory requirements is considered responsive and is encouraged.
This RFA will not support research on environmental or workplace detection technologies or targets. Diagnostic applications must focus on the goal of detection and identification of NIAID Category A, B, or C priority pathogens or toxins in human clinical samples.
Term/Amount:
This funding opportunity will use the U01 award mechanism. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. The NIAID intends to commit approximately $35 million in FY 2006 to fund 20 to 25 new and/or competitive continuation grants in response to this RFA. An applicant may request a project period of up to 5 years. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the NIAID provide support for this program, awards pursuant to this RFA are contingent on the availability of funds and the receipt of a sufficient number of meritorious applications.
Deadlines:
Release date: March 14, 2005; letter of intent receipt date: September 12, 2005; application receipt date: October 12, 2005; peer review date: February 2006; council review date: May 2006; earliest anticipated start date: August 2006; expiration date: October 13, 2005.
Complete details are available at http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-05-019.html.
